R & D to develop Execabase to combat S. aureus

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

BARDA - ASPR / DAAPPO / BARDA DCMA

Contract Value

Not provided

Codes & Classification
Solicitation Number

21C00021

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

6515

Additional Details
Set Aside

None

Place of Performance

Yonkers, New York, UNITED STATES

SourceSAM
The Biomedical Advanced Research and Development Authority (BARDA), operating under the Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Division of Acquisition and Assistance Program and Policy Operations (DAAPPO), has issued an award notice for a research and development initiative titled "R & D to develop Execabase to combat S. aureus." This procurement activity is classified under NAICS code 541714, which pertains to Research and Development in Biotechnology (except Nanobiotechnology), and is further identified by Product Service Code 6515, typically associated with medical and surgical instruments, equipment, and supplies. The primary objective of this award is to support the development of Execabase, a biotechnological solution aimed at combating Staphylococcus aureus (S. aureus), a significant pathogen responsible for a range of serious infections. The scope of work encompasses advanced research and development activities, with the intended outcome of generating innovative approaches or products that can effectively address the challenges posed by S. aureus. The project is expected to contribute to public health preparedness by advancing the state of biotechnology in this critical area. This procurement was not conducted as a fixed-price or competitive solicitation; rather, it was a negotiated award based on a Broad Agency Announcement (BAA). This approach allows for greater flexibility in project design and execution, enabling the contracting entity to engage with organizations that demonstrate unique capabilities and innovative solutions aligned with BARDA’s mission. The non-competitive, negotiated nature of the award underscores the specialized expertise required for this research and the importance of fostering innovation in the biotechnology sector. The place of performance for this contract is Yonkers, New York, United States. Contractors should note that the opportunity is managed at the federal office level, with BARDA serving as the primary contracting entity. The notice remains active as of the posting date, November 3, 2021, and further details can be accessed via the official SAM.gov opportunity listing (Opportunity ID: 098f62dad2b644ed80d8534f760dfc25). Potential contractors evaluating similar opportunities should recognize that this award reflects BARDA’s ongoing commitment to advancing research in biotechnology to address pressing public health threats. The focus on S. aureus highlights the agency’s prioritization of antimicrobial resistance and infectious disease preparedness. While specific deliverables and milestones are not detailed in the notice, the expectation is for substantive progress in the development of Execabase as a countermeasure against S. aureus. For further information or to review the official notice, interested parties are encouraged to visit the SAM.gov listing provided in the notice details.